Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization

Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization

Bibliographic Details
Main Authors:	Han, Kunkun, Xu, Xin, Chen, Guodong, Zeng, Yuanying, Zhu, Jingyu, Du, Xiaolin, Zhang, Zubin, Cao, Biyin, Liu, Zhaopeng, Mao, Xinliang
Format:	Online
Language:	English
Published:	BioMed Central 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924225/

Similar Items

A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma
by: Zhu, Jingyu, et al.
Published: (2014)

SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway
by: Han, Kunkun, et al.
Published: (2015)

Clioquinol induces pro-death autophagy in leukemia and myeloma cells by disrupting the mTOR signaling pathway
by: Cao, Biyin, et al.
Published: (2014)

A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway
by: Zhang, Zubin, et al.
Published: (2016)

The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis
by: Yujia Xu, et al.
Published: (2017-07-01)

A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivo
by: Tang, Juan, et al.
Published: (2014)

The Natural Pesticide Dihydrorotenone Induces Human Plasma Cell Apoptosis by Triggering Endoplasmic Reticulum Stress and Activating p38 Signaling Pathway
by: Zhang, Jieyu, et al.
Published: (2013)

A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo
by: Glauer, J, et al.
Published: (2013)

The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy
by: Ehrhardt, Michael, et al.
Published: (2014)

Modulation of Platelet Activation and Thrombus Formation Using a Pan-PI3K Inhibitor S14161
by: Yi, Wenxiu, et al.
Published: (2014)

Challenges in the clinical development of PI3K inhibitors
by: Massacesi, Cristian, et al.
Published: (2013)

PI3K inhibitors in inflammation, autoimmunity and cancer
by: Stark, Anne-Katrien, et al.
Published: (2015)

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances
by: Liu, Xiaochuan, et al.
Published: (2016)

Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
by: Garrett, Joan T., et al.
Published: (2011)

Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer
by: Weigelt, Britta, et al.
Published: (2012)

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
by: Akinleye, Akintunde, et al.
Published: (2013)

The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases
by: Banham-Hall, Edward, et al.
Published: (2012)

PI3K/Akt/mTOR inhibitors in breast cancer
by: Lee, Joycelyn JX, et al.
Published: (2015)

Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway
by: Ramakrishnan, Vijay, et al.
Published: (2012)

Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination
by: Sahin, I, et al.
Published: (2014)

Ferroferric oxide nanoparticles induce prosurvival autophagy in human blood cells by modulating the Beclin 1/Bcl-2/VPS34 complex
by: Shi, Min, et al.
Published: (2014)

Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
by: Tagliaferri, P, et al.
Published: (2012)

Deazaneplanocin A Is a Promising Drug to Kill Multiple Myeloma Cells in Their Niche
by: Gaudichon, Jérémie, et al.
Published: (2014)

Circulating miRNA markers show promise as new prognosticators for multiple myeloma
by: Rocci, A, et al.
Published: (2014)

MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma
by: Du, Juan, et al.
Published: (2015)

Histone deacetylase inhibitors in multiple myeloma
by: Deleu, Sarah, et al.
Published: (2009)

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
by: Yu, Yi, et al.
Published: (2015)

Cyclooxygenase-2 inhibitors: promise or peril?
by: Mengle-Gaw, Laurel J, et al.
Published: (2002)

The promise and perils of HDAC inhibitors in neurodegeneration
by: Didonna, Alessandro, et al.
Published: (2015)

Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma
by: Chen, Ming-Huang, et al.
Published: (2014)

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
by: Sweetlove, Melanie, et al.
Published: (2015)

PI3K Pathway in NSCLC
by: Martinez-Martí, Alex, et al.
Published: (2012)

Disentangling weak and strong interactions in $$B\rightarrow K^{*}(\rightarrow K\pi )\pi $$ B → K ∗ ( → K π ) π Dalitz-plot analyses
by: Jérôme Charles, et al.
Published: (2017-08-01)

Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer
by: Bhattacharya, Bhaskar, et al.
Published: (2016)

Exosomes/tricalcium phosphate combination scaffolds can enhance bone regeneration by activating the PI3K/Akt signaling pathway
by: Zhang, Jieyuan, et al.
Published: (2016)

Fangchinoline targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901 cells
by: TIAN, FENG, et al.
Published: (2015)

N-Carbamylglutamate Enhances Pregnancy Outcome in Rats through Activation of the PI3K/PKB/mTOR Signaling Pathway
by: Zeng, Xiangfang, et al.
Published: (2012)

Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application
by: Aronson, L I, et al.
Published: (2013)

MEK inhibitors as a chemotherapeutic intervention in multiple myeloma
by: Chang-Yew Leow, C, et al.
Published: (2013)

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
by: Ribatti, Domenico
Published: (2010)